« Back
Home /
Toralizumab

Toralizumab

Item no.	HY-P99325-10mg
Manufacturer	MedChem Express
CASRN	252662-47-8
Amount	10 mg
Quantity options	10 mg 1 ea 1 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.57
Dry ice	Yes
Citations	[1]Camilo E Fadul, et al. Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021 Oct 15;8(6):e1096.\|[2]Kenneth C Kalunian, et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Dec;46(12):3251-8.\|[3]Murphy, G., & Isenberg, D. A. (2019). New therapies for systemic lupus erythematosus - past imperfect, future tense. Nature reviews. Rheumatology, 15(7), 403-412.\|[4]Lassiter, G., et al., (2023). TNX-1500, a crystallizable fragment-modified anti-CD154 antibody, prolongs nonhuman primate renal allograft survival. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 23(8), 1171-1181.\|[5]Xu, H., et al., (2003). Studies investigating pretransplant donor-specific blood transfusion, rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation. Journal of immunology (Baltimore, Md.: 1950), 170(5), 2776-2782.
Smiles	[Toralizumab]
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	IDEC-131,Anti-Human CD40 ligand Recombinant Antibody
Shipping Condition	Dry ice
Available
Manufacturer - Type	Inhibitory Antibodies
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	TNF Receptor
Shipping Temperature	Dry Ice
Storage Conditions	Store at -80°C for 2 years
Molecular Weight	(145.66 kDa)
Product Description	Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease[1][2][3].
Manufacturer - Research Area	Inflammation/Immunology
Solubility	H2O
Manufacturer - Pathway	Apoptosis
Isoform	TNFRSF5/CD40
Clinical information	Phase 1

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-P99325-10mg-safety-datasheet.pdf